Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (AVHHL) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for AVITA Medical (AVHHL) over the last 7 years, with Q4 2025 value amounting to $14.0 million.

  • AVITA Medical's Cash & Equivalents fell 3647.71% to $14.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $14.0 million, marking a year-over-year decrease of 3647.71%. This contributed to the annual value of $14.0 million for FY2025, which is 3647.71% down from last year.
  • Per AVITA Medical's latest filing, its Cash & Equivalents stood at $14.0 million for Q4 2025, which was down 3647.71% from $15.4 million recorded in Q3 2025.
  • AVITA Medical's Cash & Equivalents' 5-year high stood at $115.1 million during Q1 2021, with a 5-year trough of $12.2 million in Q2 2025.
  • For the 5-year period, AVITA Medical's Cash & Equivalents averaged around $35.7 million, with its median value being $22.9 million (2022).
  • As far as peak fluctuations go, AVITA Medical's Cash & Equivalents plummeted by 7937.43% in 2022, and later surged by 11353.77% in 2023.
  • AVITA Medical's Cash & Equivalents (Quarter) stood at $55.7 million in 2021, then plummeted by 67.4% to $18.2 million in 2022, then grew by 21.77% to $22.1 million in 2023, then changed by 0.0% to $22.1 million in 2024, then tumbled by 36.48% to $14.0 million in 2025.
  • Its Cash & Equivalents stands at $14.0 million for Q4 2025, versus $15.4 million for Q3 2025 and $12.2 million for Q2 2025.